Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
26
datasets available to search
ShareScore release 0.9.0
Dataset results
26 results for “CRLM”
Hepatocellular carcinoma (HCC) Tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) Tumor microenvironment.
<p><strong>Background and purpose:</strong> While HCC is an inflammation-associated cancer, CRLM develop on permissive healthy liver microenvironment. To evaluate the immune aspects of these two different environments, peripheral blood-(PB), peritumoral-(PT) and tumoral tissues-(TT) from HCC and CRLM patients were evaluated.</p> <p><strong>Methods:</strong> 40 HCC and 34 CRLM were enrolled and freshly TT, PT and PB were collected at the surgery. PB-, PT- and TT-derived CD4<sup>+</sup>CD25<sup>+ </sup>Tregs, M/PMN-MDSC and PB-derived CD4<sup>+</sup>CD25<sup>− </sup>Teffector cells (Teffs) were isolated and characterized. Tregs function was also evaluated in the presence of the CXCR4 inhibitor, Peptide-R29, AMD3100 or anti-PD1. RNA was extracted from PB/PT/TT-tissues and tested for FOXP3, CXCL12, CXCR4, CCL5, IL-15, CXCL5, Arg-1, N-cad, Vim, CXCL8, TGFβ and VEGF-A expression.</p> <p><strong>Results:</strong> In HCC/CRLM-PB higher number of functional Tregs, CD4<sup>+</sup>CD25<sup>hi</sup>FOXP3<sup>+</sup> were detected, although PB-HCC Tregs exert a more suppressive function as compared to CRLM-Tregs. In HCC/CRLM-TT Tregs were highly represented with Activated/ENTPD-1<sup>+</sup>Tregs prevalent in HCC. As compared to CRLM, HCC overexpressed CXCR4 and N-cadherin/Vimentin in a contest rich of arginase and CCL5. Monocytic-MDSCs were highly represented in HCC/CRLM while high Polymorphonuclear-MDSCs were detected only in HCC. Interestingly, CXCR4-PB-Tregs function was impaired in HCC/CRLM by the CXCR4 inhibitor R29.</p> <p><strong>Conclusion:</strong> In HCC and CRLM, peripheral blood, peritumoral and tumoral tissues-Tregs are highly represented and functional. Nevertheless, HCC display a more immunosuppressive TME due to Tregs, MDSCs, intrinsic tumor features (CXCR4, CCL5, arginase) and the contest in which it develops. As CXCR4 is overexpressed in HCC/CRLM tumor/TME cells, CXCR4 inhibitors may be considered for double hits therapy in liver cancer patients.</p>
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model
ClinicalTrials.gov study NCT05289076. IPD Sharing: UNDECIDED. Countries: 1. Publications: 15.
The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
ClinicalTrials.gov study NCT03686254. IPD Sharing: NO. Countries: 1. Publications: 3.
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
ClinicalTrials.gov study NCT03500874. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases)
ClinicalTrials.gov study NCT03783559. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM
ClinicalTrials.gov study NCT06455254. IPD Sharing: YES. Countries: 1. Publications: 10.
HAIP Combined With Fuquinitinib as Late-line Treatment in Patients With CRLM：A Phase 2 Single-Arm Clinical Trial
ClinicalTrials.gov study NCT07024537. IPD Sharing: NO. Countries: 1. Publications: 6.
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
ClinicalTrials.gov study NCT05727163. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM
ClinicalTrials.gov study NCT06630624. IPD Sharing: NO. Countries: 1. Publications: 0.
Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to
ClinicalTrials.gov study NCT04003792. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
ClinicalTrials.gov study NCT03125161. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
ClinicalTrials.gov study NCT07381309. IPD Sharing: NO. Countries: 1. Publications: 0.
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
ClinicalTrials.gov study NCT05948072. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
ClinicalTrials.gov study NCT04940546. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
ClinicalTrials.gov study NCT03127072. IPD Sharing: Not stated. Countries: 1. Publications: 0.
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
ClinicalTrials.gov study NCT06788171. IPD Sharing: NO. Countries: 1. Publications: 0.
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
ClinicalTrials.gov study NCT06045286. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)
ClinicalTrials.gov study NCT02758977. IPD Sharing: NO. Countries: 1. Publications: 0.
Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
ClinicalTrials.gov study NCT06208371. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM
ClinicalTrials.gov study NCT06447727. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.